Reduction of Cancer Related Fatigue in Patients During TKI Therapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-05-31

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this pilot study is to determine the effects of a 12-week resistance training program on cancer related fatigue in cancer patients receiving tyrosine kinase inhibitor (TKI) therapy. It is hypothesized that incidence and severity of cancer related fatigue can be reduced by exercise training in this population which leads to an improved treatment completion rate.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Analysis of Fatigue on Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia

NCT06233890

Chronic Myeloid Leukemia Chronic Myeloid Leukemia, Chronic Phase Fatigue +1 more

ACTIVE_NOT_RECRUITING

Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer

NCT02491632

Advanced Malignant Neoplasm Fatigue Metastatic Malignant Neoplasm +2 more

ACTIVE_NOT_RECRUITING PHASE2/PHASE3

Pioglitazone Therapy Targeting Fatigue in Breast Cancer

NCT05013255

Breast Cancer Muscle Fatigue

RECRUITING PHASE2

Statin Therapy in Young Adult Survivors of Childhood Cancer

NCT01733953

Cardiovascular Disease Childhood ALL Childhood NHL

COMPLETED PHASE2

Developmental Study on Fatigue in Cancer

NCT00034450

Neoplasms

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

All Tumor Entities Treated With TKI Therapy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Strength training group

12 weeks of progressive strength training

Group Type EXPERIMENTAL

Progressive strength training

Intervention Type BEHAVIORAL

12 weeks of supervised progressive strength training

Control group

No intervention

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Progressive strength training

12 weeks of supervised progressive strength training

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female cancer patients
* Prior to tyrosine kinase inhibitor therapy (any substance, any line)
* Age: at least 18 yrs
* Body mass index (BMI): at least 18 kg/m2
* ECOG performance status: at most 2
* Must be able to meet the requirements of the study protocol

Exclusion Criteria

* Acute infectious diseases
* No ambulatory ability
* Severe neurological disorders
* Severe cardiovascular diseases
* Severe pulmonary insufficiency
* Severe renal insufficiency
* Other current tumor diseases
* Conditions rendering compliance impossible
* Participation in regular strength training

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR